Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00002043 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pneumonia, Pneumocystis Carinii HIV Infections | Drug: Dapsone | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |
Official Title: | Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
The patient must have HIV positive antibody test and presence of oral thrush or hairy leukoplakia.
- Patient must be willing and able to sign informed consent.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.
- Prophylaxis for PCP in preceding 3 months.
- Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.
- Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone.
- History of poor compliance.
Concurrent Medication:
Excluded:
- Zidovudine (AZT).
Patients with the following are excluded:
- Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.
- Prophylaxis for PCP in preceding 3 months.
- Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.
- Concurrent or prior therapy with zidovudine (AZT).
- Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone.
- History of poor compliance.
Prior Medication:
Excluded:
- Zidovudine (AZT).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002043
United States, California | |
UCLA CARE Ctr | |
Los Angeles, California, United States, 90095 |
ClinicalTrials.gov Identifier: | NCT00002043 History of Changes |
Other Study ID Numbers: |
007B |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | December 1989 |
Keywords provided by NIH AIDS Clinical Trials Information Service:
AIDS-Related Opportunistic Infections Pneumonia, Pneumocystis carinii Leukoplakia, Oral |
Dapsone AIDS-Related Complex Candidiasis, Oral |
Additional relevant MeSH terms:
HIV Infections Pneumonia AIDS-Related Complex Pneumonia, Pneumocystis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
Slow Virus Diseases Lung Diseases, Fungal Mycoses Pneumocystis Infections Dapsone Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Leprostatic Agents Anti-Bacterial Agents |